Cognitive Behavioral Treatments for Adult Posttraumatic Stress Disorder: Current Status and Future Directions

2015 ◽  
Vol 45 (4) ◽  
pp. 235-243 ◽  
Author(s):  
Matthew W. Gallagher ◽  
Johanna Thompson-Hollands ◽  
Michelle L. Bourgeois ◽  
Kate H. Bentley
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Cognitive Behavioral ◽  
Current Status ◽  
Future Directions ◽  
Behavioral Treatments

Cognitive behavioral treatments for posttraumatic stress disorder: Empirical foundation and new directions

CNS Spectrums ◽  
2013 ◽  
Vol 18 (2) ◽  
pp. 73-81 ◽  
Author(s):  
Ellen M. Koucky ◽  
Benjamin D. Dickstein ◽  
Kathleen M. Chard
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Cognitive Processing ◽  
Stress Disorder ◽  
Prolonged Exposure ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Cognitive Processing Therapy ◽  
Empirically Supported ◽  
Behavioral Treatments

Cognitive-behavioral therapy (CBT) is currently the most empirically supported intervention for posttraumatic stress disorder (PTSD) and includes both specific manualized treatments (e.g., cognitive processing therapy, prolonged exposure) and less standardized applications. As CBT for PTSD has become increasingly popular, more advanced questions have emerged regarding its use, including how existing treatments might be enhanced. In the current review, we aimed to discover recent trends in the CBT for PTSD literature by applying rigorous search criteria to peer-reviewed articles published from 2009 to 2012. Results of the 14 studies that were identified are discussed, and future directions for research are suggested.

scholarly journals Long-term outcomes of cognitive–behavioral treatments for posttraumatic stress disorder among female rape survivors.

2012 ◽  
Vol 80 (2) ◽  
pp. 201-210 ◽  
Author(s):  
Patricia A. Resick ◽  
Lauren F. Williams ◽  
Michael K. Suvak ◽  
Candice M. Monson ◽  
Jaimie L. Gradus
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Cognitive Behavioral ◽  
Long Term Outcomes ◽  
Rape Survivors ◽  
Behavioral Treatments

scholarly journals Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries

2020 ◽  
Author(s):  
Matthias A. Reinhard ◽  
Johanna Seifert ◽  
Timo Greiner ◽  
Sermin Toto ◽  
Stefan Bleich ◽  
...  
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Treatment Options ◽  
Psychiatric Inpatient ◽  
Primary Diagnosis ◽  
Current Status ◽  
German Speaking ◽  
Inpatient Settings ◽  
Prescription Rates

AbstractPosttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder with limited approved pharmacological treatment options and high symptom burden. Therefore, real-life prescription patterns may differ from guideline recommendations, especially in psychiatric inpatient settings. The European Drug Safety Program in Psychiatry (“Arzneimittelsicherheit in der Psychiatrie”, AMSP) collects inpatients’ prescription rates cross-sectionally twice a year in German-speaking psychiatric hospitals. For this study, the AMSP database was screened for psychiatric inpatients with a primary diagnosis of PTSD between 2001 and 2017. N = 1,044 patients with a primary diagnosis of PTSD were identified with 89.9% taking psychotropics. The average prescription rate was 2.4 (standard deviation: 1.5) psychotropics per patient with high rates of antidepressant drugs (72.0%), antipsychotics drugs (58.4%) and tranquilizing drugs (29.3%). The presence of psychiatric comorbidities was associated with higher rates of psychotropic drug use. The most often prescribed substances were quetiapine (24.1% of all patients), lorazepam (18.1%) and mirtazapine (15.0%). The use of drugs approved for PTSD was low (sertraline 11.1%; paroxetine 3.7%). Prescription rates of second-generation antipsychotic drugs increased, while the use of tranquilizing drugs declined over the years. High prescription rates and extensive use of sedative medication suggest a symptom-driven prescription (e.g., hyperarousal, insomnia) that can only be explained to a minor extent by existing comorbidities. The observed discrepancy with existing guidelines underlines the need for effective pharmacological and psychological treatment options in psychiatric inpatient settings.

Sign in / Sign up

Export Citation Format

Share Document